重组人促红素与铁剂联合治疗新生儿贫血的临床效果

Clinical Effect of Recombinant Human Erythropoietin Combined With Chalybeate in Treatment of Neonatal Anemia

目的探讨新生贫血患儿接受重组人促红素联合铁剂的临床效果。方法按照信封法将恩平市人民医院收治的40例新生贫血患儿分为对照组(n=20)和观察组(n=20)。对照组接受常规治疗,观察组以此为基础实施3周铁剂治疗并联合重组人促红素。比较两组血液指标、NBNA评分及贫血治疗安全性。结果治疗前两组各项指标差异无统计学意义(P>0.05),观察组患儿经3周治疗后网织红细胞、血红蛋白、血细胞比容、重组人促红细胞生成素、红细胞水平、原始反射、行为能力、被动肌张力及主动肌张力评分均高于对照组,不良反应发生率低于对照组(P<0.05)。结论铁剂与重组人促红素治疗新生儿贫血可改善患儿各项能力和血液指标,提升贫血治疗安全性,降低不良反应发生率,效果显著。

Objective To investigate clinical effect of recombinant human erythropoietin combined with chalybeate for neonatal anemia.Methods The paper chose 40 cases neonatal anemia in our hospital according to envelope method,and divided them into control group(n=20)and observation group(n=20).Control group was treated with routine treatment,and observation group with chalybeate combined with recombinant human erythropoietin for 3 weeks.Blood indexes,NBNA scores and safety of anemia treatment were compared between two groups.Results There was no significant difference between two groups before treatment(P>0.05).After 3 weeks of treatment,reticulocyte,hemoglobin,hematocrit,recombinant human erythropoietin,erythrocyte level,primitive reflex,behavioral ability,passive muscle tone and active muscle tone scores in observation group were higher than control group,incidence of adverse reactions was lower than control group(P<0.05).Conclusion Chalybeate and recombinant human erythropoietin can improve ability and blood indexes of neonatal anemia,improve safety of anemia treatment,and reduce incidence of adverse reactions,with significant effect.